Article Correctness Is Author's Responsibility: Recurrent GBM brain tumors with few mutations respond best to immunotherapy

(Duke University Medical Center) New insights from a team led by Duke's Preston Robert Tisch Brain Tumor Center provide potential answers about why immunotherapies have limited success against brain tumors. The team found that recurring glioblastoma tumors with very few mutations are far more vulnerable to immunotherapies than similar tumors with an abundance of mutations.